Monica Heger tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb.
The direct-to-consumer firm offers whole-genome sequencing for under $1,000, along with specific reports on pharmacogenomics, health traits, and certain diseases.
Take2 Health plans to launch an nasopharyngeal carcinoma early detection test in the next several months in Hong Kong and southern China.
New methods for spatial transcriptomic profiling include a sequential FISH-based method and one that makes use of DNA-barcoded bead arrays.
The company plans to present early data this year from its collaboration with Johnson & Johnson to develop a nasal swab-based lung cancer genomic classifier.
The UW researchers have filed for a patent on the variable voltage method but have not disclosed commercialization plans.
Illumina said that the DTC market is in "transition" from ancestry and genealogy to one driven by demand for health information.
The method builds on a previous technique the group developed to measure transcriptomes and surface proteins from single cells.
Both teams had sequencing data generated at BGI and said that going forward, it would be important to validate the technology outside of BGI.
The firm's technology uses short oligo probes that target RNA directly on a pathology slide, allowing users to select regions of interest to profile.
The test will run on Oxford Nanopore's MinIon and will be used as a reflex test when the standard PCR test does not give a clear answer.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.